Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.35 -1.97% 17.40 17.30 17.50 17.50 17.30 17.50 36,754 16:35:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.9 -2.0 - 44

C4x Discovery Share Discussion Threads

Showing 2751 to 2769 of 2850 messages
Chat Pages: 114  113  112  111  110  109  108  107  106  105  104  103  Older
DateSubjectAuthorDiscuss
27/4/2022
13:14
I agree but on the flipside we know when they do announce something it is meaty, not just flannel and filler announcements to get themselves noticed.

What I enjoyed about Clive's most recent interview was the fact they are spreading their wings now into other areas, as they have exhausted the areas they have been working on since day one. As there are still molecules with no partnerships yet, that suggests to me that partnership announcements are not far away.

alloa2003
27/4/2022
12:44
For a company of few words, hopefully we'll get some meat on the bone as to a advancements made, including the Sanofi deal which was over a year ago! Since that, they have released absolutely zero to the market regarding updates, progress etc. They need to work on their IR badly but despite that I have full confidence that Clive will bring home the bacon!
copandrobber
27/4/2022
06:47
We must be due some news on a new partnership.
alloa2003
26/4/2022
16:40
Got em all in an isa ready for the big move
bloomberg2
26/4/2022
12:55
Moving ahead of the results
alloa2003
19/4/2022
06:39
C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")



Notice of Results



19 April 2022- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, will be announcing its interim results for the six months ended 31 January 2022 on Thursday 28 April 2022

alloa2003
13/4/2022
15:58
In case anyone missed it, the INDIVIOR update on Phase 1 SAD of Orexin 1 Inhibitor INDV 2000) was published Feb 16 in the Q4 21 results. The report says Phase 1 MAD is on clinical hold at the instruction of the FDA based on "nonclinical findings from another similar development programme not sponsored by Indivior". However, "major progress" made on formulation and chemical development


https://www.indivior.com/en/investors/results-reports-presentations

t0pgrader
07/4/2022
19:46
Licensing news?
t0pgrader
15/3/2022
00:02
Seems to be a little bit of interest today
alloa2003
10/3/2022
16:43
Down into the close yet again !
bloomberg2
08/3/2022
16:34
Anyone about ?
bloomberg2
01/3/2022
08:57
DaveMac3,

This all started with a badly handled share sale a couple of months ago and the shares have never really got going again. Personally from what I hear I dont think they will need a fund raising but things can change.

alloa2003
01/3/2022
08:34
Chart breaking down a bit, they need a deal or milestone soon or the talk will turn to another fund raise
davemac3
17/2/2022
11:04
Yes your absolutely right there Ewan.. Can't be long now surly
bloomberg2
17/2/2022
10:42
They don't report R&D on the results - you need to follow the link to their quarterly R&D report. Just had a look and there's no new news - still having to do additional toxicology study.
ewanwhose
16/2/2022
08:33
Indivior full year results out!! Can't see any updates on our Orexin-Receptor antagonist C4X 3256 !! ?
bloomberg2
15/2/2022
19:04
Yes - awaiting deal news
t0pgrader
15/2/2022
12:52
Any one here
bloomberg2
03/2/2022
07:41
RNS: Grant of Options and Directors Dealing
livewireplus
Chat Pages: 114  113  112  111  110  109  108  107  106  105  104  103  Older
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230205 18:00:22